Beijing Biopharmaceutical Technology Foresight Research In Sight Of Global Competitiveness Improvement

As an innovation leading industry, not only as the fundamental impetus to upgrade the biopharmaceutical industrial structure and economy development; technological innovation is also the key factor that determines the industrial global competitive capability. As a result of the rapid development of life sciences and the industrial technology, biopharmaceutical critical technology and development model is uncertainty to choose, which brings risk to the government finance management and input of enterprise R&D. Therefore, as a new kind of strategic management tool combining technology and economy development as well as integrating efficiently all kinds of resources for optimized disposition, technology foresight would benefit government management of technical resources and forecast technical trend.and it has already made remarkable achievements in global and domestic practice.With methods of expert consultation, biblometrics and competition analysis, on the basis of technology foresight research, the study did tendency analysis on the development of global biopharmaceutical industry while discussing the present situation and rules of technological development, together with the investigation of Beijing's technical advantage, industrial demand and the supporting technology platform. With the finding of critical technology area of regional industry and evaluating technology competitive capability and its affecting factors, the conclusion of strategic advice was put forward on the innovation of biopharmaceutical technology in Beijing.According to the industry technical classification six sub-areas was divided, which are genetic engineering and vaccine, functional genomics and proteomics, antibody engineering and antibody drug, stem cell and tissue engineering, enzyme and fermentation engineering, diagnostic reagent, with 25 branch technologies set below. The study carries SCI literature and patent metrics on each sub-area, US is in the absolute leading position globally, Europe and Japan rank the next. China has advantages in some areas, ranking eighth in the whole world; However, Beijing is still far behind other areas gathered with biopharmaceutical industry, such as Boston, Cambridge, Tokyo, but superior to Shanghai and Singapore. Biopharmaceutical patents are owned mostly by universities, companies and academies of US, Europe and Japan, among which, the companies take the main status of innovation. The biopharmaceutical research in China doesn't develop in synchronization with the global trend, for example, recombinant proteins and antibodies, the technology trends has entered the platform or dropping stage in developed countries, but it still at the fast rising stage in China, which shows that the development of overall biopharmaceutical technology level is lagging behind, with very big disparity with the overseas as a whole.The technology foresight on Beijing biopharmaceutical indicates that, the genetic recombinant protein, therapeutic vaccine for critical diseases, preventive vaccine for critical infectious diseases, research on genetic engineering antibody as well as antibody for critical diseases are the most important key technologies; But the research and development of clinical diagnostic reagent based on the biomarkers of antibody, fast diagnostic reagent for infectious diseases or tumor, preventive vaccines for critical infectious diseases, clinical diagnostic chips are the easiest technologies to realize. The cluster analysis shows that the vaccine and the diagnostic area with the industrial advantage are the one should be given priority to development.The technological innovation of regional biopharmaceutical industry also faces the risks of technical substitution, patent barriers, immature market or merger and acquisition, as for the government, economic risks brought by fund input and policies or risks of missing the development opportunity need to be avoided in the developing process.